Loading...
OTCMHBPCF
Market cap31mUSD
Nov 14, Last price  
0.45USD
Name

Helix Biopharma Corp

Chart & Performance

D1W1MN
OTCM:HBPCF chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-16.04%
Rev. gr., 5y
%
Revenues
0k
3,424,0003,591,0003,841,0004,434,0004,532,0004,260,000000000000000
Net income
-9m
L+47.28%
-7,674,000-6,964,000-14,102,000-14,469,000-11,348,000-17,440,000-1,570,000-8,701,000-8,743,000-9,682,000-10,073,000-8,654,000-7,527,000-9,010,000-7,911,000-6,080,000-6,290,000-9,264,000
CFO
-5m
L-5.57%
-6,079,000-6,997,000-13,157,000-12,193,000-10,339,000-14,112,000-7,814,000-7,692,000-8,488,000-8,853,000-9,295,000-7,524,000-5,531,000-10,826,000-9,304,000-6,509,000-5,527,000-5,219,000
Earnings
Jun 12, 2025

Profile

Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. The company is headquartered in Richmond Hill, Canada.
URL
https://www.helixbiopharma.com/
IPO date
Jun 03, 1996
Employees
7
Domiciled in
CA
Incorporated in
CA

Valuation

Title
CAD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑072023‑072022‑072021‑072020‑072019‑072018‑072017‑072016‑072015‑07
Income
Revenues
Cost of revenue
6,109
5,593
5,151
Unusual Expense (Income)
NOPBT
(6,109)
(5,593)
(5,151)
NOPBT Margin
Operating Taxes
(132)
14
(484)
Tax Rate
NOPAT
(5,977)
(5,607)
(4,667)
Net income
(9,264)
47.28%
(6,290)
3.45%
(6,080)
-23.14%
Dividends
Dividend yield
Proceeds from repurchase of equity
5,506
4,151
6,205
BB yield
-53.81%
-21.85%
Debt
Debt current
2,468
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
(1,081)
(808)
(784)
Cash flow
Cash from operating activities
(5,219)
(5,527)
(6,509)
CAPEX
(14)
(10)
Cash from investing activities
(14)
(5)
Cash from financing activities
5,506
3,088
6,205
FCF
(6,732)
(4,727)
(4,655)
Balance
Cash
1,081
808
3,252
Long term investments
Excess cash
1,081
808
3,252
Stockholders' equity
(52,099)
(44,982)
(37,271)
Invested Capital
52,009
44,137
40,058
ROIC
ROCE
6,787.78%
661.89%
EV
Common stock shares outstanding
44,486
38,646
149,487
Price
0.23
 
0.19
-77.11%
Market cap
10,232
 
28,403
-75.18%
EV
9,151
27,619
EBITDA
(6,095)
(5,580)
(5,139)
EV/EBITDA
Interest
7
14
18
Interest/NOPBT